Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia

Leukemia

Volumn 20, Issue 8, 2006, Pages 1408-1413

  Moon, H W ^a   Shin, S ^b   Kim, H Y ^c,d   Kim, Y R ^e   Cho, H I ^d   Yoon, S S ^d   Park, S ^d   Kim, B K ^d   Chun, H ^d   Kim, H C ^d   Park, C J ^f   Min, Y H ^g   Lee, D Soon ^c,d  

^a Ewha Womans University School of Medicine   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c National Research Laboratory for Molecular Cell Imaging   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Jeju National University School of Medicine   (South Korea)

^f University College of Medicine   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

Author keywords

AML1 ETO rearrangement; Differentiation; G CSF; G CSF receptor

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ETO; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL CLONING; CELL DIFFERENTIATION; CELL MATURATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; INFECTION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 33746157336     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404286     Document Type: Article

References (23)

1. Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): Implications for future therapeutical strategies. Eur J Haematol 2004; 72: 89-106.
2. Shimizu K, Kitabayashi I, Kamada N, Abe T, Maseki N, Suzukawa K et al. AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon. Blood 2000; 96: 288-296.
3. Metcalf D. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature 1989; 339: 27-30.
4. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991; 78: 2791-2808.
5. Fukunaga R, Ishizaka-Ikeda E, Nagata S. Purification and characterization of the receptor for murine granulocyte colony-stimulating factor. J Biol Chem 1990; 265: 14008-14015.
6. Nicholson SE, Novak U, Ziegler SF, Layton JE. Distinct regions of the granulocyte colony-stimulating factor receptor are required for tyrosine phosphorylation of the signaling molecules JAK2, Stat3, and p42, p44MAPK. Blood 1995; 86: 3698-3704.
7. Dong F, Liu X, de Koning JP, Touw IP, Hennighausen L, Larner A et al. Stimulation of Stat5 by granulocyte colony-stimulating factor (G-CSF) is modulated by two distinct cytoplasmic regions of the G-CSF receptor. J Immunol 1998; 161: 6503-6509.
8. Xavier L, Cunha M, Goncalves C, Teixeira Mdos A, Coutinho J, Ribeiro AC et al. Hematological remission and long term hematological control of acute myeloblastic leukemia induced and maintained by granulocyte-colony stimulating factor (G-CSF) therapy. Leuk Lymphoma 2003; 44: 2137-2142.
9. Takamatsu Y, Miyamoto T, Iwasaki H, Makino S, Tamura K. Remission induction by granulocyte colony-stimulating factor in hypoplastic acute myelogenous leukemia complicated by infection. A case report and review of the literature. Acta Haematol 1998; 99: 224-230.
10. Ferrara F, Di Noto R, Viola A, Russo C, Boccuni P, Costantini S et al. Complete remission in acute myeloid leukaemia with t(8;21) following treatment with G-CSF: Flow cytometric analysis of in vivo and in vitro effects on cell maturation. Br J Haematol 1999; 106: 520-523.
11. Nimubona S, Grulois I, Bernard M, Drenou B, Godard M, Fauchet R et al. Complete remission in hypoplastic acute myeloid leukemia induced by G-CSF without chemotherapy: Report on three cases. Leukemia 2002; 16: 1871-1873.
12. Lee DY, Cho HI, Kang YH, Yun SS, Park SY, Lee YS et al. The role of fluorescence in situ hybridization (FISH) for monitoring hematologic malignancies with BCR/ABL or ETO/AML1 rearrangement: A comparative study with FISH and G-banding on 919 consecutive specimens of hematologic malignancies. Cancer Genet Cytogenet 2004; 152: 1-7.
13. Lee KY, Suh BG, Kim JW, Lee W, Kim SY, Kim YY et al. Varying expression levels of colony stimulating factor receptors in disease states and different leukocytes. Exp Mol Med 2000; 32: 210-215.
14. Camera A, Volpicelli M, Villa MR, Risitano AM, Rossi M, Rotoli B. Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation). Haematologica 2002; 87: 1225-1227.
15. Piccaluga PP, Martinelli G, Malagola M, Rondoni M, Bianchini M, Visani G et al. Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature. Haematologica 2003; 88: ECR28.
16. Matsushima T, Saitoh T, Karasawa M, Takizawa M, Miyawaki S, Nojima Y et al. Effect of cytokines on growth and differentiation of leukaemic cells with translocation t(6;9)(p23;q34). Br J Haematol 2001; 115: 812-816.
17. Delwel R, Dorssers L, Touw I, Wagemaker G, Lowenberg B. Human recombinant multilineage colony stimulating factor (interleukin-3): stimulator of acute myelocytic leukemia progenitor cells in vitro. Blood 1987; 70: 333-336.
18. Colombat P, Santini V, Delwel R, Krefft J, Bredmond JL, Lowenberg B. Primary human acute myeloblastic leukaemia: An analysis of in vitro granulocytic maturation following stimulation with retinoic acid and G-CSF. Br J Haematol 1991; 79: 382-389.
19. Lee KW, Choi IS, Roh EY, Kim DY, Yun T, Lee DS et al. Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21): A single institution's experience. Ann Hematol 2004; 83: 218-224.
20. Klampfer L, Zhang J, Zelenetz AO, Uchida H, Nimer SD. The AML1/ETO fusion protein activates transcription of BCL-2. Proc Natl Acad Sci USA 1996; 93: 14059-14064.
21. Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G et al. AML1-ETO downregulates the granulocytic differentiation factor C/ EBPalpha in t(8;21) myeloid leukemia. Nat Med 2001; 7: 444-451.
22. Rhoades KL, Hetherington CJ, Harakawa N, Yergeau DA, Zhou L, Liu LQ et al. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 2000; 96: 2108-2115.
23. Kutlay S, Beksac M, Dalva K, Ilhan O, Koc H, Akan H et al. The detection of flow cytometric G-CSF receptor expression and it's effect on therapy in acute myeloid leukemia. Leuk Lymphoma 2003; 44: 791-795.